SEC Form 4 · accession 0001209191-19-000500
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Theodore Alan Huizenga
Officer — VP, Controller and PAO
Period of report
Jan 2, 2019
Accepted (ET)
Jan 2, 2019 · 7:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 2, 2019 | M | 2,448 | $21.00 | A | 14,505 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $21.00 | Jan 2, 2019 | M | 2,448 | D | — | Jan 29, 2024 | Common Stock | 2,448 | 17,000 | D |
Explanation of responses
- F1Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- F2Includes 117 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2018.
- F31/4th of the option vested one year from January 29, 2014 and then 1/48th monthly thereafter.